Al­ny­lam, Roche’s RNAi can­di­date scores mid-stage win in hy­per­ten­sion

Al­ny­lam’s zilebe­sir­an met the pri­ma­ry end­point and cer­tain sec­ondary end­points in a Phase II dose-rang­ing tri­al in a read­out that ar­rived less than six weeks …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER